Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D

Executive Summary

Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
Advertisement

Related Content

Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
Lilly Touts Its R&D Reorganization And Pipeline Prospects, But A Looming Patent Cliff And Risky Bets Take Center Stage
Pharma’s Pipeline Getting Fuller; Parexel Finds 8.2% Jump In Trial Starts
Pharma’s Pipeline Getting Fuller; Parexel Finds 8.2% Jump In Trial Starts
Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts
Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts
Advertisement
UsernamePublicRestriction

Register

PS048076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel